United States - English - NLM (National Library of Medicine)

sandoz inc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 250 ug in 1 ml - digoxin injection is indicated for the treatment of mild to moderate heart failure in adults. digoxin injection increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin injection should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin injection increases myocardial contractility in pediatric patients with heart failure. digoxin injection is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin injection is contraindicated in patients with: risk summary experience with digoxin in pregnant women over several decades, based on published retrospective clinical studies and case reports, has not led to the identification of a drug associated risk of major birth defects, miscarriage or adverse maternal and

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.25 mg in 1 ml - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. digoxin should be given to a pregnant woman only if clearly needed.  it is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. animal reproduction studies have not been conducted with digoxin. there are not enough data from clinical trials to determine the safety and efficacy of digoxin during labor and delivery. studies have shown that digoxin distributes into breast milk and that the milk-to-serum concentration ratio is approximately 0.6-0.9. however, the estimated exposure of a nursing infant to digoxin via breastfeeding is far below the usual infant maintenance dose. therefore, this amount should have no pharmacologic effect upon the infant. the safety and effectiveness of digoxin in the control of ventricular rate in children with atrial fibrillation have not been established. the safety and effectiveness of digoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies. however, in published literature of children with heart failure of various etiologies (e.g., ventricular septal defects, anthracycline toxicity, patent ductus arteriosus), treatment with digoxin has been associated with improvements in hemodynamic parameters and in clinical signs and symptoms. newborn infants display considerable variability in their tolerance to digoxin. premature and immature infants are particularly sensitive to the effects of digoxin, and the dosage of the drug must not only be reduced but must be individualized according to their degree of maturity. the majority of clinical experience gained with digoxin has been in the elderly population. this experience has not identified differences in response or adverse effects between the elderly and younger patients. however, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function [see dosage and administration (2.1)] . the clearance of digoxin can be primarily correlated with the renal function as indicated by creatinine clearance. table 3 provides the usual daily maintenance dose requirements for digoxin based on creatinine clearance [see dosage and administration (2.3)] . digoxin is primarily excreted by the kidneys; therefore, patients with impaired renal function require smaller than usual maintenance doses of digoxin [see dosage and administration (2.3)] . because of the prolonged elimination half-life, a longer period of time is required to achieve an initial or new steady-state serum concentration in patients with renal impairment than in patients with normal renal function. if appropriate care is not taken to reduce the dose of digoxin, such patients are at high risk for toxicity, and toxic effects will last longer in such patients than in patients with normal renal function. plasma digoxin concentrations in patients with acute hepatitis generally fall within the range of profiles in a group of healthy subjects. the absorption of digoxin is reduced in some malabsorption conditions such as chronic diarrhea.

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.25 mg in 1.0 ml - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: digoxin should be given to a pregnant woman only if clearly needed.  it is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. animal reproduction studies have not been conducted with digoxin. there are not enough data from clinical trials to determine the safety and efficacy of digoxin during labor and delivery. studies have shown t

Kenya - English - Pharmacy and Poisons Board

aurochem laboratories (india) pvt. ltd 8, palghar taluka industrial co-op. estate - digoxin 0.25mg tablets - tablet - digoxin 0.25mg tablets - cardiac glycosides: digitalis glycosides

Canada - English - Health Canada

pharmascience inc - digoxin - tablet - 0.0625mg - digoxin 0.0625mg - cardiotonic agents

Canada - English - Health Canada

pharmascience inc - digoxin - tablet - 0.125mg - digoxin 0.125mg - cardiotonic agents

Canada - English - Health Canada

pharmascience inc - digoxin - tablet - 0.25mg - digoxin 0.25mg - cardiotonic agents

United States - English - NLM (National Library of Medicine)

rebel distributors corp - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. newborn infants display considerable variability in their tolerance to digoxin. premature and immature infants are particularly sensitive to the effec

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - digoxin - tablet - 250 microgram(s) - digitalis glycosides; digoxin